Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase
- PMID: 7106170
- DOI: 10.1007/BF00548404
Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase
Abstract
Deuterated methadone (M-d3) and GCMS were used to study the pharmacokinetics of methadone (M) during the induction stage of methadone maintenance treatment (MMT). A pulse dose of M-d3 was given on Days 1 and 25 of two dosage regimens, one with a continuous 30 mg dose (n = 6), and the other with 30 mg for 10 days, followed by 60 mg as the maintenance dose (n = 6). Plasma and urinary levels of M and M-d3 were measured throughout and plasma half-lives, oral bioavailabilities and volumes of distribution were calculated from the data of Days 1-2 and 24-26. The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min. A consistent finding was a lower urinary pH and increased renal clearance during the first month of treatment. The shorter elimination half-lives in those patients probably caused unacceptably high fluctuation in the body content of M during the 24 h dosage interval, and may have interfered therefore, with its therapeutic effectiveness.
Similar articles
-
Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.Eur J Clin Pharmacol. 1983;25(4):497-501. doi: 10.1007/BF00542117. Eur J Clin Pharmacol. 1983. PMID: 6653644
-
Clinical pharmacokinetics of methadone.Acta Anaesthesiol Scand Suppl. 1982;74:66-9. doi: 10.1111/j.1399-6576.1982.tb01850.x. Acta Anaesthesiol Scand Suppl. 1982. PMID: 6953740
-
Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.Eur J Clin Pharmacol. 1979 Aug;16(1):53-7. doi: 10.1007/BF00644967. Eur J Clin Pharmacol. 1979. PMID: 499301
-
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003. Clin Pharmacokinet. 2002. PMID: 12405865 Review.
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
Cited by
-
Analgesie mit Methadon.Schmerz. 1989 Sep;3(3):155-65. doi: 10.1007/BF02527398. Schmerz. 1989. PMID: 18415356 German. No abstract available.
-
A comparison of the effects of a macrobiotic diet and a Western diet on drug metabolism and plasma lipids in man.Eur J Clin Pharmacol. 1987;33(4):403-7. doi: 10.1007/BF00637638. Eur J Clin Pharmacol. 1987. PMID: 3443147
-
Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.Anesth Analg. 2013 Jul;117(1):52-60. doi: 10.1213/ANE.0b013e3182918252. Epub 2013 Jun 3. Anesth Analg. 2013. PMID: 23733841 Free PMC article.
-
In silico ordinary differential equation/partial differential equation hemodialysis model estimates methadone removal during dialysis.J Pain Res. 2015 Jul 22;8:417-29. doi: 10.2147/JPR.S84615. eCollection 2015. J Pain Res. 2015. PMID: 26229501 Free PMC article.
-
Pharmacokinetics of opioids in liver disease.Clin Pharmacokinet. 1999 Jul;37(1):17-40. doi: 10.2165/00003088-199937010-00002. Clin Pharmacokinet. 1999. PMID: 10451781 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical